Bader, Gerd

BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy

Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research

Angiogenesis and VEGF in CancerLymphatic System and Diseases

Cited by 1,056

Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker

Solca, F., Dahl, G., Zoephel, A., Bader, G., Sanderson, M., Klein, C., Kraemer, O., Himmelsbach, F., Haaksma, E., & Adolf, G. R. (2012) · The Journal of Pharmacology and Experimental Therapeutics

HER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations

Cited by 865

BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design

Farnaby, W., Koegl, M., Roy, M. J., Whitworth, C., Diers, E., Trainor, N., Zollman, D., Steurer, S., Karolyi-Oezguer, J., Riedmueller, C., et al. (2019) · Nature Chemical Biology

Protein Degradation and InhibitorsChromatin Remodeling and Cancer

Cited by 562

Chemically Induced Degradation of the Oncogenic Transcription Factor BCL6

Kerres, N., Steurer, S., Schlager, S., Bader, G., Berger, H., Caligiuri, M., Dank, C., Engen, J. R., Ettmayer, P., Fischerauer, B., et al. (2017) · Cell Reports

Protein Degradation and InhibitorsLymphoma Diagnosis and Treatment

Cited by 207

Highly Selective PTK2 Proteolysis Targeting Chimeras to Probe Focal Adhesion Kinase Scaffolding Functions

Popow, J., Arnhof, H., Bader, G., Berger, H., Ciulli, A., Covini, D., Dank, C., Gmaschitz, T., Greb, P., Karolyi-Özguer, J., et al. (2019) · Journal of Medicinal Chemistry

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 138

Efficacy of the highly selective focal adhesion kinase inhibitor BI 853520 in adenocarcinoma xenograft models is linked to a mesenchymal tumor phenotype

Hirt, U. A., Waizenegger, I. C., Schweifer, N., Haslinger, C., Gerlach, D., Braunger, J., Weyer-Czernilofsky, U., Stadtmüller, H., Sapountzis, I., Bader, G., et al. (2018) · Oncogenesis

Cell Adhesion Molecules ResearchCancer Cells and Metastasis

Cited by 63

Discovery and characterization of brigimadlin, a novel and highly potent MDM2-p53 antagonist suitable for intermittent dose schedules

Gollner, A., Rudolph, D., Weyer-Czernilofsky, U., Baumgartinger, R., Jung, P., Weinstabl, H., Ramharter, J., Grempler, R., Quant, J., Rinnenthal, J., et al. (2024) · Molecular Cancer Therapeutics

Cancer-related Molecular PathwaysCancer Mechanisms and Therapy

Cited by 18